JP7720911B2 - 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物 - Google Patents

痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物

Info

Publication number
JP7720911B2
JP7720911B2 JP2023532743A JP2023532743A JP7720911B2 JP 7720911 B2 JP7720911 B2 JP 7720911B2 JP 2023532743 A JP2023532743 A JP 2023532743A JP 2023532743 A JP2023532743 A JP 2023532743A JP 7720911 B2 JP7720911 B2 JP 7720911B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pregabalin
pain
tramadol
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023532743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504902A (ja
JP2024504902A5 (https=
Inventor
ジャネット ムニョス マルティネス セシリア
アレジャンドロ ゴンザレス カヌダス ホルヘ
ヤズミン オレルビデス ルビオ パオラ
セラフィン エスピノザ レオン シクスト
クアフテンコス エスコバル エルネスト
Original Assignee
ラボラトリオス シラネス、エセ．ア．デ セ．べ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトリオス シラネス、エセ．ア．デ セ．べ． filed Critical ラボラトリオス シラネス、エセ．ア．デ セ．べ．
Publication of JP2024504902A publication Critical patent/JP2024504902A/ja
Publication of JP2024504902A5 publication Critical patent/JP2024504902A5/ja
Application granted granted Critical
Publication of JP7720911B2 publication Critical patent/JP7720911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023532743A 2020-12-04 2020-12-04 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物 Active JP7720911B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050050 WO2022119430A1 (es) 2020-12-04 2020-12-04 Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor

Publications (3)

Publication Number Publication Date
JP2024504902A JP2024504902A (ja) 2024-02-02
JP2024504902A5 JP2024504902A5 (https=) 2025-05-13
JP7720911B2 true JP7720911B2 (ja) 2025-08-08

Family

ID=81853431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532743A Active JP7720911B2 (ja) 2020-12-04 2020-12-04 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物

Country Status (10)

Country Link
US (1) US20240000727A1 (https=)
EP (1) EP4230199A4 (https=)
JP (1) JP7720911B2 (https=)
KR (1) KR20230117591A (https=)
CA (1) CA3199166A1 (https=)
CO (1) CO2023008896A2 (https=)
DO (1) DOP2023000095A (https=)
MX (1) MX2022015331A (https=)
PE (2) PE20252763A1 (https=)
WO (1) WO2022119430A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048294A2 (en) 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20150313892A1 (en) 2014-02-07 2015-11-05 Trinity Laboratories, Inc. Pharmaceutical compositions for treating pain associated with dysmenorrhea
WO2020044070A1 (es) 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US20020187996A1 (en) 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
KR20060108692A (ko) 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
MX2007008833A (es) 2005-01-21 2008-03-25 Pharmanova Inc Formulaciones farmaceuticas y metodos de uso.
JP2007018123A (ja) 2005-07-06 2007-01-25 Kyocera Mita Corp 画像処理装置、及び画像処理システム
MXPA05011735A (es) 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
CL2008003800A1 (es) 2007-12-21 2010-01-22 Synthon Bv Sal de acido sulfonico de pregabalina, procedimiento de preparacion, composicion farmaceutica, util para tratar trastornos neuropsiquiatricos, esquizofrenia, epilepsia, fibromialgia, trastorno de ansiedad generalizada, trastorno de panico y fobia social y dolor por ejemplo dolor neuropatico.
TR200909613A1 (tr) 2009-12-22 2011-07-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Pregabalinin farmasötik bileşimleri.
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
WO2018015946A1 (en) 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
MX2017016720A (es) 2017-12-19 2019-06-20 Monte Verde S A Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba).
KR20190075718A (ko) * 2017-12-21 2019-07-01 주식회사 네비팜 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048294A2 (en) 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20150313892A1 (en) 2014-02-07 2015-11-05 Trinity Laboratories, Inc. Pharmaceutical compositions for treating pain associated with dysmenorrhea
WO2020044070A1 (es) 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático

Also Published As

Publication number Publication date
CA3199166A1 (en) 2022-06-09
MX2022015331A (es) 2023-02-01
PE20252750A1 (es) 2025-12-05
WO2022119430A1 (es) 2022-06-09
KR20230117591A (ko) 2023-08-08
JP2024504902A (ja) 2024-02-02
PE20252763A1 (es) 2025-12-22
EP4230199A1 (en) 2023-08-23
US20240000727A1 (en) 2024-01-04
EP4230199A4 (en) 2024-07-31
DOP2023000095A (es) 2023-06-15
CO2023008896A2 (es) 2023-08-18

Similar Documents

Publication Publication Date Title
KR101607112B1 (ko) 타펜타돌 조성물
US20070020335A1 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
US20080026054A1 (en) Novel anelgesic combination
MXPA02011610A (es) Combinacion de sustancia activa que contiene un opioide que tiene una estructura tipo fentanilo y cetamina.
WO2015121218A1 (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
ZA200600159B (en) Novel solid pharmaceutical composition comprising amisulpride
JP2005537221A (ja) トラマドールの徐放性製剤
JP7720911B2 (ja) 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
US6902746B2 (en) Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
EP4268813A1 (en) Fixed combination medicine for the control and management of neuropathic pain
JP2018513138A (ja) ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形
US20250228797A1 (en) Synergic and stable pharmaceutical composition of an nsaid and an opioid analgesic for pain and inflammation
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US12296051B2 (en) Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
KR20200067406A (ko) 베포타스틴의 방출 제어형 경구 제제
CA3061243C (en) Idalopirdine-based combinatorial therapies of alzheimer's disease
CN107921042A (zh) 包含氨氯地平和右美沙芬的药物组合物
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
AU2019211135A1 (en) Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
HK1237271A1 (en) Tapentadol compositions

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250331

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250729

R150 Certificate of patent or registration of utility model

Ref document number: 7720911

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150